Title: Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia and NAFLD

Short title: Bile acids in meta-inflammatory disorders

Oscar Chávez-Talavera MD ^{+,1, 2, 3, 4,}, Anne Tailleux PhD ^{+,1, 2, 3, 4,}, Philippe Lefebvre PhD ^{1, 2, 3, 4,}, Bart Staels PhD * ^{1, 2, 3, 4,}.

⁺ These authors contributed equally

¹ Univ. Lille, U1011 - EGID, F-59000 Lille, France

² Inserm, U1011, F-59000 Lille, France

³ CHU Lille, F-59000 Lille, France

⁴ Institut Pasteur de Lille, F-59000 Lille, France

Abbreviations: ASBT (apical-sodium-dependent BA transporter); BA (bile acids); BAAT (bile acid-CoA:amino acid N-acyltransferase); BACS (bile acid:CoA synthase); BAS (bile acid sequestrants); BAT (brown adipose tissue); WAT (white adipose tissue); BSEP (bile salt export pump); BSH (bile salt hydrolase); NAFLD (non-alcoholic fatty liver disease); NASH (non-alcoholic steatohepatitis).

* Corresponding author: Prof Bart STAELS

Institut Pasteur de Lille, 1 rue du professeur Calmette, BP245, 59019 LILLE - France

Tel: +33320877388 - Fax: +33320877360

e-mail: bart.staels@pasteur-lille.fr

Disclosure: The authors declare no conflict of interest.

Abstract

Bile acids are signaling molecules, which coordinately regulate metabolism and inflammation *via* the nuclear farnesoid X receptor (FXR) and the Takeda G protein-coupled receptor 5 (TGR5). These receptors activate transcriptional networks and signaling cascades controlling the expression and activity of genes involved in bile acid, lipid and carbohydrate metabolism, energy expenditure, and inflammation by acting predominantly in entero-hepatic tissues, but also in peripheral organs. In this review, we discuss the most recent findings on the inter-organ signaling and interplay with the gut microbiota of bile acids and their receptors in meta-inflammation, with a focus on their pathophysiological roles in obesity, type 2 diabetes, dyslipidemia and non-alcoholic steatohepatitis and their potential therapeutic applications.

Key words: Bile acids; FXR; TGR5; meta-inflammation.

Enterohepatic Circulation and Metabolism of Bile Acids

Bile acids (BA) are amphipathic steroid molecules synthesized from cholesterol in hepatocytes surrounding the hepatic central vein (perivenous hepatocytes) by the action of ~15 enzymes. BA synthesis occurs *via* two pathways¹. The classical pathway, initiated by the rate-limiting enzyme cytochrome P450 cholesterol 7 α -hydroxylase (CYP7A1), produces the majority of the BA pool. A fraction of the BA pool is synthesized *via* an alternative pathway (between 3-18% of total BA synthesis in healthy humans^{2,3}), initiated by cytochrome P450 27 α -hydroxylase (CYP27A1). The products of these pathways are the primary BA cholic acid (CA), and chenodeoxycholic acid (CDCA) in humans¹. In rodents, α - and β -muricholic acid (MCA) are formed from CDCA and ursodesoxycholic acid (UDCA) respectively, by CYP2C70⁴. The hydrophobicity index of the BA pool, reflecting the ratio of highly hydroxylated CA(+MCA) to lower hydroxylated BA (such as CDCA), is an important parameter controlling its physiological functions. This hydrophobicity index differs between rodents (low hydrophobicity) and humans (high hydrophobicity) due to the conversion of CDCA into MCA in rodents. CDCA and MCA synthesis is conditioned by the activity of 12 α -hydroxylase CYP8B1, which transforms di-hydroxylated- in tri-hydroxylated-BA. BA synthesis, which follows a circadian rhythm controlled by the clock gene *Rev-erba*⁵ and the KLF15-Fgf15 axis⁶, is regulated by negative feedback mechanisms. High hepatic BA exposure inhibits BA synthesis *via* the Farnesoid X Receptor (FXR), which decreases LXR1-regulation of CYP7A1 *via* induction of Small Heterodimer Protein (SHP/NR0B2) in the liver. BA also induce fibroblast growth factor-19 (FGF19, the human orthologue of murine FGF15) expression and release from the intestine, which activates the FGFR4/ β klotho receptor in the liver, thus collectively leading to inhibition of hepatic CYP7A1 and CYP8B1 expression^{7,8}.

In hepatocytes, primary BA are further conjugated to glycine -mainly in humans- or taurine -mainly in mice- at the C24 position by the enzymes BA-CoA synthase (BACS) and BA-CoA–amino acid N-acetyltransferase (BAAT). Moreover, BA can also be sulfated by the sulfotransferase SULT2A1 (SULT2A9 in mice), or glucuronidated by UDP-glucuronosyltransferases, such as UGT2B4, UGT2B7 and UGT1A3¹. BA are then secreted into the bile canaliculi *via* the bile salt export pump (BSEP) and the BA transporters MRP2 and MDR1A¹. The bile containing the secreted BA flows through the biliary tree into the gallbladder, where it is stored and concentrated during the inter-digestive period, until meal ingestion-stimulated cholecystokinin (CCK) secretion by enteroendocrine I-cells induces gallbladder contraction, causing bile release into the duodenum¹.

In the intestine, BA activate pancreatic lipase and form micelles containing dietary fat and lipophilic vitamins (A, D, E and K). The intestinal microbiota transforms primary BA into secondary BA: deoxycholic acid (DCA), lithocholic acid (LCA) and UDCA in humans; and DCA, LCA, ω MCA, hyodeoxycholic (HDCA) and murideoxycholic (MDCA) acid in mice⁹. In the enterocytes from the distal ileum, 95% of intestinal BA are actively re-absorbed through the apical-sodium-dependent BA transporter (ASBT/SLC10A2) and secreted at the basolateral membrane by the heterodimeric organic solute transporters α and β (OST α/β). The unabsorbed 5% of intestinal BA are either deconjugated by the gut microbiota and passively reabsorbed in the colon or lost into feces. The absorbed BA return to the liver through the superior mesenteric and portal veins, where they are cleared by active transporters in the sinusoidal membrane of hepatocytes (NTCP, OAT, OATP, mEH)¹⁰. Within hepatocytes, free BA are conjugated and secreted into bile canaliculi along with BA newly synthesized from cholesterol, thereby compensating for fecal loss. The small amount of BA

escaping hepatic recapture reaches the peripheral tissues *via* the systemic circulation. These plasma BA circulate bound to plasma proteins -mainly albumin (~80%) and lipoproteins (~20%)¹¹- where they may exert signaling functions on peripherally-expressed BA receptors¹.

Reciprocal Interaction between Intestinal Microbiota and Bile Acids: Impact on Host Metabolism

In the intestinal lumen, BA and the microbiota reciprocally control their composition. The gut microbiota transforms BA, present in the intestine at millimolar concentrations, by carrying out numerous reactions, such as hydrolysis of conjugated BA by bile salt hydrolases (BSH); 7 α -dehydroxylation of CA and CDCA, forming DCA and LCA, respectively; and oxidation and epimerization of hydroxyl groups at the C3, C7 and C12 positions. The gut microbiota also esterify BA, making them more hydrophobic. Esterified BA (ethyl-esters and long-chain fatty acid esters of LCA and polyesters of DCA) account for approximately 25% of fecal BA⁹. Furthermore, intestinal bacteria reduce the bactericidal effect of BA by transforming DCA and LCA into iso-DCA and iso-LCA (3 β -OH epimers) *via* the iso-BA pathway¹². Indeed, BA act as anti-microbial agents by damaging bacterial membranes and altering intracellular macromolecular structures through detergent actions. Therefore, only microbial populations able to tolerate high BA concentrations can survive in the gut. Whereas free BA are more damaging to bacterial membranes, taurine catabolic end-products promote proliferation of some bacteria strains¹³.

BSH is active in *Lactobacillus*, *Bifidobacterium*, *Firmicutes*, *Enterococcus*, *Clostridium*, and *Bacteroides*, and produces free BA, taurine and glycine. Free BA solubilize intestinal lipids and are reabsorbed less efficiently, resulting in increased

fecal BA loss and an ameliorated metabolic adaptation of the host¹⁴. Indeed, BSH-over-expressing *E.coli* reduce host weight gain, liver triglycerides and plasma cholesterol in conventionally raised mice by reducing intestinal cholesterol absorption and increasing hepatic uptake of plasma cholesterol for *de novo* BA synthesis to compensate for the fecal BA loss¹⁴.

Gut microbial depletion in germ-free or antibiotic-treated rodents increases the proportion of taurine-conjugated primary BA species –including T β MCA, a rodent-specific FXR antagonist (see below)-, decreases the diversity of the BA pool¹⁵ and concomitantly increases gallbladder and small intestine BA concentrations¹⁶. In line, treatment of mice with probiotics, such as VSL#3, which enhances deconjugation and fecal excretion of BA, increases hepatic BA synthesis *via* down-regulation of the FXR/FGF15 axis¹⁷. Intriguingly, colonization of germ-free mice with human microbiota decreases the formation of secondary BA species, especially the FXR antagonist T β MCA, thereby increasing ileal FXR activity and FGF15 expression¹⁸. As BA receptors have different affinities for distinct BA species (see below), the gut bacteria may hence modulate metabolism and host physiology by altering BA pool composition⁹.

Since type 2 diabetes (T2D), obesity and non-alcoholic fatty liver disease (NAFLD) are associated with dysbiosis¹⁹ and changes of the BA pool size and composition^{20–22}, the interaction of gut microbiota with BA metabolism and its impact on these pathophysiological conditions is of great interest. For instance, NASH patients present dysbiosis associated with increases in BA synthesis, fecal primary BA and the primary:secondary BA ratio²³.

Treatment with antibiotics alters gut bacteria composition. In antibiotic-treated mice²⁴, BSH-producing *Lactobacillus* decreases, synthesis of the FXR antagonist T β MCA increases, and high-fat diet (HFD)-induced obesity, insulin resistance and NAFLD improve (see below)²⁵. However, studies in humans reported no metabolic changes after pro-biotic supplementation²⁶ or anti-microbial therapy²⁷. Hence, although an interplay between BA, gut microbiota and metabolic diseases is evident, the causality and directionality of the interactions remain unclear.

Bile Acid Metabolism in Meta-Inflammatory Disorders

Crosstalk between metabolically active tissues is necessary for proper energy homeostasis. In obesity, T2D and non-alcoholic steatohepatitis (NASH), these organs often present, in combination with metabolic alterations, a chronic low-grade inflammation characterized by the recruitment of immune inflammatory cells, abnormal cytokine and acute-phase reactant production, and inflammasome activation, referred to as “meta-inflammation”²⁸.

Meta-inflammatory disorders, such as obesity, T2D and NASH, are associated with changes in BA metabolism and pool composition as shown by a large number of observational studies (Table). Chronic inflammation modulates hepatic BA metabolism, as exemplified by the decrease of CYP7A1 transcription in human hepatocytes treated with IL-1 β , which acts *via* the JNK/c-Jun signaling pathway²⁹. Total BA concentrations increase in obese patients and correlate with body mass index (BMI) irrespective of T2D and NAFLD (Table). In T2D patients, systemic total BA concentrations are increased, in the fasting and post-prandial states. However, reported changes in qualitative BA pool composition differ among studies (Table).

Interestingly, insulin-resistant, but not T2D patients, display an increased 12 α -hydroxylated:non12 α -hydroxylated BA ratio²⁰.

In NASH patients, plasma BA and C4³⁰, as well as hepatic BA concentrations, are increased^{23,31}. Moreover, hepatic BA synthesis may shift to the alternative pathway in livers of NASH patients²¹ as suggested by gene expression analysis. The higher BA exposure could lead to cytotoxicity and contribute to the pathogenesis of NAFLD³⁰.

Fasting peripheral blood BA concentrations consistently increase upon bariatric surgery (Roux-en-Y gastric bypass, RYGB) in humans (Table) and preclinical models³². Again, reported qualitative changes of the BA pool after bariatric surgery differ between studies, which may be due to differences in methodological parameters (feeding state, time after surgery). The kinetics of BA pool size and composition alterations after RYGB are unclear: while some studies reported an early 2 to 3-fold increase in BA^{33–35}, others found BA to be increased only one year post-RYGB^{36–38} or after 20% of body weight loss³⁹. Both short term⁴⁰ and long term^{35,37,39–41} augmentations in post-prandial systemic BA concentrations were reported after RYGB, with qualitative changes such as increased conjugated BA species^{37,41}. However, the changes in peripheral BA were not correlated to changes in body weight after RYGB⁴². The 12 α -hydroxylated:non12 α -hydroxylated BA ratio was increased 2 years after RYGB³⁵, even though insulin resistance improved. Interestingly, patients with RYGB-induced remission of T2D presented higher BA concentrations than patients without remission⁴³, suggesting a role for the BA in the metabolic improvements.

There is scarce information regarding BA changes after vertical sleeve gastrectomy (VSG), bilio-pancreatic diversion and laparoscopic adjustable gastric banding (LAGB)

(Table). In some studies, fasting plasma BA did not change after LAGB^{34,39} or VSG⁴⁴; while others reported a decrease upon 20% weight loss after LAGB³⁹ and an increase 1 year after VSG³⁸.

The mechanisms underlying the increase in peripheral BA upon RYGB surgery are still unclear and may include increased hepatic synthesis, increased intestinal recapture potentially associated with microbiota alterations, changes in portal blood flow and/or lower hepatic BA recapture from the portal vein^{45–48}. Interestingly, germ-free mice receiving gut microbiota from RYGB-treated mice exhibit weight loss and decreased fat mass⁴⁷, suggesting that intestinal microbiota could contribute to the metabolic improvements after RYGB *via* changes in the BA pool.

Alterations in FXR and TGR5 signaling could contribute to the metabolic improvements. Indeed, BA and GLP-1 levels positively correlate after RYGB^{38,49} and VSG in humans³⁸ and in mice⁵⁰. FGF19 has also been reported to increase after RYGB^{33,43} and VSG⁴⁴. Direct roles for FXR and TGR5 in the metabolic improvements after VSG have been suggested based on genetic studies in mice^{48,50,51}.

Since BA have emerged as signaling molecules regulating glucose, lipid and energy homeostasis, and inflammation, it is conceivable that changes in BA pool size and composition in metabolic diseases and upon bariatric surgery alter BA signaling pathways, impacting on metabolic parameters. However, due to methodological heterogeneity and cohort size, it is still unclear how BA pool alterations contribute to and impact on (patho)physiological conditions in humans.

Bile Acids: Signaling Molecules Modulating Meta-Inflammatory Diseases

BA are ligands of the nuclear receptors FXR⁵², vitamin D receptor (VDR)⁵³ and pregnane X receptor (PXR)⁵⁴ as well as G-protein coupled receptors (GPCR) such as TGR5⁵⁵, sphingosine-1-phosphate receptor (S1PR)²⁵⁶, and the muscarinic receptors M2/3⁵⁷. Activation of nuclear receptors by BA requires cellular entry, either by simple diffusion, in the case of hydrophobic free BA, or by active transport for conjugated and hydrophilic BA. In contrast to nuclear receptors, ligands can bind directly to cell surface receptors¹. Activation of PXR⁵⁴, VDR^{53,58} and CAR⁵⁹ by BA, mainly LCA, induce a xenobiotic detoxification response to stimulate BA excretion under cholestatic conditions¹. We will here focus on the role of BA in the control of metabolism and inflammation *via* FXR, TGR5 (Figure1) and S1PR2.

FXR (*NR1H4*) is expressed in several organs, including the liver, intestine, kidneys, adrenal glands, white adipose tissue (WAT) and immune cells¹. Natural FXR agonists are CDCA>DCA>CA>LCA, in order of decreasing potency, while T α -, T β -MCA and possibly UDCA are antagonists¹⁶. Ligand-bound FXR forms a heterodimer with Retinoic-X-Receptors (RXR α , β or γ) to regulate target gene expression. FXR also indirectly represses gene transcription *via* induction of negative regulators, such as SHP, competition for other nuclear receptors (peroxisome proliferator-activated receptor (PPAR) α ⁶⁰) or transcriptional coregulators (CRTC2⁶¹). In addition to ligands, post-translational modifications also modulate the transcriptional activity of FXR, such as O-GlcNAcylation⁶², methylation, acetylation⁶³ and phosphorylation (*via* AMPK and PKC)^{64–66}. Interestingly, acetylation of FXR increases inflammation and deteriorates glucose metabolism by interfering with its sumoylation and transrepressive activity⁶⁷.

TGR5 (encoded by the *GPBAR1* gene) is expressed in enteroendocrine L-cells^{68,69}, brown adipose tissue (BAT), WAT, skeletal muscle, gallbladder, non-parenchymal liver cells and the brain¹. BA activate TGR5 with different potencies

(LCA>DCA>CDCA>CA). TGR5 activation induces adenylate-cyclase to produce cAMP, which in turn activates protein-kinase A to exert immediate cytosolic effects, or activate the transcription factor cAMP-Responsive Element Binding protein (CREB) to modulate gene expression¹.

Conjugated BA activate S1PR2 in hepatocytes, which activates, *via* the ERK1/2 and Akt signaling pathways, nuclear sphingosine kinase-2 (SphK2). This enzyme, which synthesizes S1P from sphingosine, hence increasing S1P levels in the nucleus. Nuclear S1P inhibits specific histone deacetylases, thus increasing histone acetylation and inducing enzymes involved in lipid and sterol metabolism. By modulating expression of nuclear receptors (including FXR) and proteins involved in lipid and glucose metabolism (LDL-R, SREBP1c and FAS), S1PR2/SphK2/S1P signaling lowers hepatic lipid content. Indeed, S1PR2-deficient mice develop hepatic steatosis upon HFD, whereas S1PR2 over-expression prevents hepatic steatosis^{56,70}.

Energy metabolism

Distinct AT depots differentially express BA receptors, FXR and TGR5 being expressed in white^{71,72} and brown^{73,74} adipocytes, respectively. Moreover, both receptors are also expressed in certain immune-inflammatory cells in AT, which may contribute to their anti-inflammatory and insulin-sensitizing effects. The gut microbiota promote diet-induced obesity in a FXR-dependent manner in mice⁷⁵. In AT, FXR regulates adipocyte differentiation and functions by promoting PPAR gamma activity and interfering with the Wnt/ β -catenin pathway^{72,76}. In BAT, TGR5 stimulates energy expenditure⁷³ by inducing the expression of iodothyronine-deiodinase type 2 (DIO2), thus converting inactive thyroxine (T4) into 3,5,3'-triiodothyronine (T3), which activates the thyroid hormone receptor to uncouple mitochondrial function and to

increase thermogenesis, and PPAR γ coactivator-1 α (PGC-1 α), a regulator of mitochondrial biogenesis⁷³.

FXR and TGR5 may be involved in the metabolic improvement induced by VSG. The impact of VSG on body weight and glucose tolerance appears reduced in FXR-deficient mice⁴⁸. TGR5 may mediate the effect of surgery on metabolism by enhancing production of the incretin glucagon-like peptide-1 (GLP-1)^{50,51}, and on body weight *via* TGR5 activation in BAT⁵⁰. Upon VSG in mice, TGR5 deficiency reduces the 12 α hydroxylated:non-12 α hydroxylated BA ratio and BA pool hydrophobicity potentially by decreasing CYP8B1⁵¹. BA also modulate energy expenditure by inducing intestinal expression and secretion of FGF15/19. Administration of FGF19 to HFD-fed mice enhances the metabolic rate and insulin sensitivity, and decreases body weight⁷⁷. The increase of FGF19 associated with T2D remission following RYGB may thus also contribute to the metabolic improvements following surgery in humans⁴³. Moreover, pharmacological activation of intestinal FXR with fexaramine, a synthetic FXR agonist with intestine-restricted bioavailability, induces FGF15 in mice, reducing diet-induced weight gain, systemic inflammation and hepatic glucose production⁷⁸. FGF15 induces changes in BA pool composition and increases TGR5 ligand production, leading to both BAT activation, enhanced thermogenesis and WAT browning⁷⁸. Oral administration of CDCA to healthy humans increased BAT activity and energy expenditure likely *via* TGR5 activation in brown adipocytes⁷⁴, making TGR5 a target to treat obesity.

Lipid metabolism

FXR regulates lipid and lipoprotein metabolism by acting on hepatic lipogenesis, and lipoprotein secretion, intravascular remodeling and plasma clearance, as well as intestinal cholesterol absorption (Figure2).

FXR reduces TG-rich lipoproteins by several mechanisms. FXR reduces lipogenesis by repressing hepatic SREBP1c expression in SHP-⁷⁹ and FGF15/19-dependent manners⁸⁰. FXR also represses microsomal triglyceride transfer protein (MTP) and apolipoprotein (apo) B gene expression⁸¹ thus reducing VLDL secretion⁷⁹. FXR enhances lipoprotein lipase (LPL) activity by increasing expression of apoCII⁸² –a LPL activator- while reducing apoCIII⁸³ –a LPL inhibitor- stimulating intravascular lipolysis of TG-rich lipoproteins. Furthermore, FXR increases VLDL-Receptor (VLDL-R) expression⁸⁴. The inhibition of BA synthesis from cholesterol upon FXR activation results in increased hepatic cholesterol concentrations, hence LDL-R activity decreases and plasma LDL-C increases.

Levels of Lp(a), an atherogenic lipoprotein, decrease due to reduced hepatic apo(a) gene expression through concerned actions of hepatic FXR and FGF19⁸⁵. Interestingly, cholestatic patients present low Lp(a) levels, which increase after removal of the biliary obstruction⁸⁵. FXR also acts on reverse cholesterol transport (RCT) and HDL metabolism by decreasing apoA1⁸⁶, increasing Scavenger Receptor–B1 (SR-B1)⁸⁷ and CETP⁸⁸ expression, thus increasing HDL-C clearance and lowering plasma HDL-C levels *in vivo*. FXR activation thus induces a combination of pro- and anti-atherogenic lipoprotein profile changes. Further attention is thus required to evaluate the impact of FXR activation on cardiovascular risk.

In humans, CDCA and the semi-synthetic FXR agonist obeticholic acid (OCA, INT-747 or 6-Ethyl-CDCA, Intercept Pharmaceuticals) increase LDL-C^{89,90}, likely *via* FXR-dependent CYP7A1 inhibition, thus decreasing hepatic cholesterol conversion to BA, increasing hepatic cholesterol content, and inhibiting LDL-Receptor (LDL-R) activity (Figure2). In humans, CDCA treatment decreases hepatic mRNA levels of LDL-R

and hydroxymethylglutaryl-Co-enzymeA (HMG-CoA) reductase –the rate-limiting enzyme of cholesterol synthesis⁹¹. By contrast, in the mouse, OCA inhibits cholesterol absorption and increases RCT, *via* hepatic- but not intestinal-FXR⁹².

The hydrophobicity index and conjugation state of the BA pool is an important determinant of intestinal dietary cholesterol and lipid absorption⁹², with a more hydrophobic BA pool being most efficient for intestinal cholesterol absorption. In line, CYP7A1^{-/-} mice are protected from HFHC-induced metabolic disorders likely due to upregulation of the alternative BA synthesis pathway and hence a more hydrophilic BA pool⁹³. Importantly, studies in mice explaining the increase in RCT⁹² and trans-intestinal cholesterol excretion (TICE) upon FXR activation⁹⁴ by modifications in the hydrophobicity index of the BA pool, are unlikely to translate to human pathophysiology, as hydrophobic CDCA will predominate in humans vs hydrophilic MCA in rodents.

BA sequestrants (BAS) are anionic exchange resins that trap BA in the intestinal lumen increasing fecal BA output, hence decreasing intestinal FXR activity. As a consequence, lower amounts of BA and FGF15/19 reach the liver, deactivating hepatic FXR hence inducing CYP7A1-mediated conversion of cholesterol to BA, increasing LDL-Receptor (LDL-R) expression and thus lowering LDL-C. Concomitantly, the inhibition of lipogenesis by FXR is attenuated. In agreement, BAS decrease LDL-C and increase HDL-C, while also increasing plasma triglycerides and hepatic lipid accumulation. The LRC-CPPT trial showed that the BAS cholestyramine significantly reduced coronary heart disease death in hypercholesterolemic patients⁹⁵.

Glucose metabolism

BA regulate glucose homeostasis by acting directly on FXR and TGR5 in the intestine, liver and pancreas, and indirectly by promoting FXR-dependent induction of intestinal FGF15/19 (Figure3). In humans, FGF19 is also produced by the gallbladder⁹⁶ and in mice, FGF15 is produced in the hypothalamus where it signals to lower glucagon production⁹⁷.

In the intestine, FXR modulates the kinetics of glucose absorption, which is delayed in FXR-deficient mice⁹⁸. FXR reduces post-prandial glucose utilization by inhibiting hepatic glycolysis and lipogenesis^{79,99,100}, whereas FGF15/19 increases glycogenesis¹⁰¹. Thus, in the post-prandial state, FXR lowers splanchnic glucose utilization (Figure3).

In enteroendocrine L-cells, BA regulate the production and secretion of GLP-1 *via* opposite effects on TGR5 and FXR. Activation of TGR5, whose expression parallels L-cell density along the gastrointestinal tract with maximal expression in the colon, induces preproglucagon gene expression and GLP-1 secretion^{69,102}. Since TGR5 is rather expressed at the basolateral, than at the apical L-cell membrane, absorption and local release of its agonists appears a pre-requisite for its activation¹⁰³. By contrast, FXR activation represses preproglucagon gene expression and GLP-1 secretion in the ileum by inhibiting glycolysis and ChREBP activity in L-cells¹⁰⁴. Since TGR5-mediated cytosolic signaling is rapid, whereas transcriptional regulation by FXR is slow, and since FXR expression is more proximal than TGR5 in the intestine, these receptors likely exert opposing effects on GLP-1 production, which are, however, separated in time and space.

FXR and TGR5 are both expressed in pancreatic β -cells, where they positively regulate synthesis and glucose-induced secretion of insulin^{105,106}. Moreover, TGR5 activation in pancreatic α -cells induces pro-convertase-1 expression, shifting

glucagon production to GLP-1, hence increasing β -cell mass and function in a paracrine manner¹⁰⁷. Perturbations in hepatic glucose metabolism alter BA synthesis, impacting on FXR-regulated β -cell glucose-stimulated insulin secretion¹⁰⁸, identifying a liver-pancreas BA signaling connection.

BAS treatment improves also glucose homeostasis, and colestyramine is a FDA-approved oral antidiabetic drug. Chronic treatment with BAS deactivates FXR in intestinal L-cells, enterocytes and hepatocytes, increasing GLP-1 synthesis and secretion, decreasing intestinal glucose absorption, enhancing hepatic glycolysis and lipogenesis thus promoting splanchnic glucose utilization¹⁰⁹ (Figure3). In accordance, pharmacological inactivation or genetic deficiency of FXR in the intestine improve energy and glucose homeostasis^{110,111} and NASH due to decreased intestinal ceramide production²⁵. Moreover, the BAS sevelamer decreases steatosis, lobular inflammation and endotoxemia in western diet-fed mice¹¹². Together, most observations suggest that inactivation of intestinal FXR results in an improved metabolic profile, although treatment with the intestinal-selective FXR agonist fexaramine was also reported to improve metabolism⁷⁸.

Inhibition or deficiency of CYP8B1 improves glucose homeostasis by increasing GLP-1 in mice. The decreased CA:MCA ratio upon CYP8B1-deficiency mice impairs micellar absorption of fats and nutrients, increasing luminal free fatty acids in the ileum and GLP-1 secretion¹¹³. Furthermore, MCA may inhibit intestinal FXR, which enhances GLP-1 production¹⁰⁴. However, translation of these findings to humans is unlikely (see above).

Initial studies suggested a role of FXR in the regulation of hepatic gluconeogenesis by decreasing the expression of the rate-limiting enzymes phosphoenolpyruvate carboxy-kinase (PEPCK), glucose-6-phosphatase (G6Pase) and fructose-1,6-

biphosphatase-1 (FBP1)^{114,115}. However, other studies reported that FXR activation induces PEPCK¹¹⁶ and that PEPCK and G6Pase are lowered in FXR-deficient mice^{99,115}. FXR-deficient mice submitted to a fasting-refeeding schedule presented an accelerated response to high carbohydrate refeeding with induction of glycolytic and lipogenic genes and a pronounced repression of gluconeogenic genes, with concomitant hypoinsulinaemia and hypoglycemia⁹⁹. These studies all employed different conditions in which gluconeogenesis was evaluated (*in vivo*, *in vitro*, fasting, refeeding, HFD...). Thus, the exact role of FXR in fasting-induced gluconeogenesis is still unclear and requires further studies. Similarly, conflicting data exist in humans, since OCA treatment increases insulin-sensitivity measured using hyperinsulinemic-euglycemic clamps in T2D/NASH patients¹¹⁷, whereas HOMA-IR increased in NASH patients in the FLINT trial⁹⁰.

Immune function

FXR and TGR5 are expressed in several immune cell types. TGR5 exerts anti-inflammatory activities, decreasing cytokine production in monocytes, macrophages¹¹⁸, Kupffer¹¹⁹ and human dendritic cells¹²⁰. TGR5 activation reduces HFD-induced glucose intolerance, insulin resistance and inflammation by inhibiting NLRP3 inflammasome activation *via* the TGR5-cAMP-PKA axis in mice¹²¹. Furthermore, TGR5 activation protects against LPS-induced inflammation¹²², atherosclerosis¹²³ and experimental autoimmune encephalitis¹¹⁸.

Overexpression of CYP7A1 decreases hepatic inflammatory cell infiltration, pro-inflammatory cytokine production and fibrosis in methionine/choline-deficient diet-fed mice by decreasing hepatic free cholesterol, oxidative stress in a FXR-, but not TGR5-dependent manner¹²⁴. Intestinal FXR activation with OCA decreased the pro-

inflammatory genes IL-1 β , IL-6 and macrophage chemoattractant protein-1 (MCP-1) in the colon, lowering trinitrobenzensulfonic acid or dextran sodium sulfate-induced inflammation in mouse colonic mucosa^{125,126}. Moreover, FXR-deficiency impairs intestinal barrier function, which may enhance hepatic LPS exposure and inflammation¹²⁷.

NASH/NAFLD

NAFLD is a progressive liver disease, which initiates with hepatic steatosis and can progress to inflammation and hepatocyte ballooning (NASH), fibrosis, cirrhosis and finally hepatocarcinoma. Besides contributing to liver-related mortality, NAFLD is also strongly associated with a high cardiovascular disease risk. Promoter hypermethylation is inversely correlated to the expression of the CYP27A1, OST α , BACS and OATP genes in NAFLD livers, which could lead to liver and systemic toxicity¹²⁸. FXR activation may reduce NAFLD, as it reduces steatosis by inhibiting lipogenesis, decreases chemically-induced hepatic inflammation and fibrosis in rats¹²⁹ and maintains intestinal barrier integrity, thus protecting the liver from bacteria-derived inflammatory signals¹²⁷. Since FXR expression is low in quiescent and activated stellate cells, its effects on fibrosis may be indirect¹³⁰.

A recent large randomized placebo-controlled trial in patients with biopsy-diagnosed NASH showed that OCA treatment improves the histological NAFLD Activity Score and fibrosis of the liver⁹⁰. However, OCA treatment also reduces HDL- and increases LDL-cholesterol and HOMA-IR. In line, OCA reduces the secretion of inflammatory and fibrotic factors, but increases apoB secretion in an *in vitro* reconstituted human liver model¹³¹. These effects on lipids, also observed in healthy individuals¹³², and glucose homeostasis are potentially restricting the clinical use of such semi-synthetic

BA compounds and call for the design of Selective BA Receptor Modulators (SBARMs) devoid of such side-effects.

Therapeutic Modulation of Bile Acid Metabolism

Given the role of BA signaling in the regulation of meta-inflammation, altering the BA pool and BA receptor activities may be valuable therapeutic options to treat meta-inflammatory disorders^{133,134}.

TGR5

Based on their ability to promote energy expenditure in BAT, GLP-1 secretion in enteroendocrine L-cells and anti-inflammatory properties, TGR5 agonists may be useful in the treatment of obesity and T2D. Semi-synthetic BA-derivatives INT-777⁶⁹ and non-steroidal TGR5 agonists^{135,136} improve glucose homeostasis in preclinical models. Unfortunately, systemic exposure to TGR5 agonists increases gallbladder volume^{135,136} and promotes pruritus¹³⁷. The ideal molecule would thus be a topical intestinal agonist with limited, local absorption to reach the basolateral membrane of L-cells, but without systemic exposure to avoid cholecystomegaly. This would thus preserve GLP-1 secretion, but unfortunately also preclude BAT activation.

FXR

Due to their inhibitory effects on lipogenesis and hepatic fibrosis, FXR agonists, such as OCA, are in development for NASH treatment. Other FXR non-steroidal agonists are GW4064, Px-104 (Phenex), WAY-362450 (Wyeth), EDP-305 and EP-024297 (Enanta Pharmaceuticals), fexaramine, LJN452 (Novartis Pharmaceuticals) and GS-9674 (Phenex-Gilead), some of which are in clinical development. As discussed,

intestinal antagonism of FXR appears to improve metabolic control, whereas hepatic FXR activation may improve hepatic fibrosis. FXR inactivation triggered with BAS has beneficial effects on diabetes and hypercholesterolemia, but increases plasma triglycerides and hepatic steatosis, which precludes their use in patients with hypertriglyceridaemia.

FGF19

Due its metabolic effects¹⁰¹, FGF19 is a candidate to treat NASH and obesity-related disorders, but FGF19 may increase the risk of cancer. The recombinant FGF19 mimetic peptide NGM282, currently clinically tested in metabolic liver disease, does not induce cell proliferation. Surprisingly, anti-sense FGFR4¹³⁸ (ISIS) has also been shown to induce fat burning and energy expenditure in mice. However, potential species differences between FGF19 and FGF15 signaling call for cautions when interpreting FGF19 studies in rodents.

CYP8B1

Based on the beneficial metabolic phenotype of CYP8B1-deficiency¹¹³, inhibition of CYP8B1 by decreasing the 12 α -hydroxylated:non12 α -hydroxylated BA ratio has potential therapeutic implications. However, CYP8B1 inhibition results in opposite changes in physicochemical properties of the BA pool in humans vs rodents. Moreover, it induces the FXR antagonist MCA in rodents, whereas the FXR agonist CDCA is predominant in humans, cautioning the extrapolation of rodent studies to humans.

ASBT-I

The impairment of intestinal BA reuptake by inhibiting ASBT improves features of NAFLD and insulin-sensitivity in HFD-fed mice¹³⁹. Similar as BAS, ASBT inhibitors (ASBT-I) reduce intestinal BA absorption, decreasing hepatic BA supply and thus FXR activation, resulting in de-repression of CYP7A1 and enhanced conversion of cholesterol to BA. Moreover, shifting BA to the distal part of intestine may sustain TGR5-induced GLP-1 secretion as, in contrast to resins, free BA absorption is not impaired upon ASBT-I treatment. Further studies on ASBT-I should be performed to assess the efficacy and safety of this approach in humans or relevant models¹³⁹.

NorUDCA

Finally, the UDCA derivative norUDCA improves hepatic steatosis in mice^{140,141}. NorUDCA does not activate FXR/TGR5, but may exert FXR antagonistic effects inhibiting intestinal FGF19, enhancing BA synthesis and decreasing plasma cholesterol, but possibly increasing lipogenesis¹⁴².

Conclusion and perspectives

The high BA concentrations in entero-hepatic tissues regulate metabolism in an inter-organ dialogue between the intestine, its microbiota, and the liver. In turn, the liver secretes BA, hence modulating intestinal metabolism. In peripheral organs, BA also contribute to metabolic homeostasis, even though their concentrations are lower in the systemic circulation. Thus, impaired BA metabolism likely contributes to the pathophysiology of metabolic diseases (obesity, T2D and NASH). The bidirectional effects between intestinal microbiota and BA suggest that dysbiosis and associated alterations in BA homeostasis may interactively contribute to the metabolic

dysregulations seen in T2D, obesity and NAFLD, as well as their remission upon bariatric surgery.

An important remaining question is whether FXR should be activated or inhibited in the intestine and/or liver to reverse metabolic abnormalities and NAFLD. Intestinal-specific FXR deactivation, either by natural/chemical antagonism or BA sequestration, prevents obesity, T2D and NAFLD/NASH in rodents (Figure4). Contradictorily, fexaramine, reportedly exerting exclusively intestinal FXR-specific actions, confers similar beneficial effects. A systematic comparison of the activity of FXR agonists and antagonists on the intestinal FXR signaling pathway could provide clues about their mechanism of action, as they clearly differ in their ability to activate subsets of FXR target genes and thus act as SBARMs¹⁴³. In addition, exploring their ability to affect the gut microbiota, and vice-versa, may also identify reasons for their different biological activities.

In the liver, FXR exerts hepatoprotective activities, improving steatosis, inflammation and fibrosis (Figure 4). An important unresolved question is whether, through treating with metabolically-stable, highly-active synthetic BA analogues, interfering permanently with the FXR signaling pathway, whose functions differ in fasting and fed conditions, and BA synthesis, which is submitted to circadian fluctuations, may in the long term induce unwanted effects.

Based on existing preclinical data and clinical use of BAS, it appears that an orally administered inhibitor of intestinal FXR would be preferential to improve glucose and cholesterol metabolism, whereas a liver-targeted FXR agonist would improve liver function and fibrosis.

Caution should also be taken when translating data from preclinical murine models to humans, since BA pool modulation affects the hydrophobicity index differently in mice

vs humans, and mice produce the FXR antagonist T β MCA, absent in humans. The recent identification of the enzyme responsible for MCA synthesis in mice will allow the development of humanized-BA pool murine models. Finally, most beneficial effects of the FGF15/19 pathway have been observed by treating mice with supra-pharmacological concentrations of human recombinant FGF19, which could, due to species-specific differences, result in erroneous extrapolations. Further studies in this exciting field will determine whether pharmacological modulation of the novel BA metabolism targets (TGR5, FXR, ASBT, FGF19, CYP8B1) will convey beneficial clinical effects in humans.

Acknowledgments

BS is a member of the Institut Universitaire de France and OC-T a participant of the PECCEM program, Faculty of Medicine, UNAM, Mexico City, Mexico. This work was supported by grants from the European Genomic Institute for Diabetes (E.G.I.D., ANR-10-LABX-46) and the European Research Council (ERC Grant Immunobile, contract 694717).

References

1. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. *Physiol Rev* 2009;89:147–191.
2. Vlahcevic ZR, Stravitz RT, Heuman DM, et al. Quantitative estimations of the contribution of different bile acid pathways to total bile acid synthesis in the rat. *Gastroenterology* 1997;113:1949–1957.
3. Duane WC, Javitt NB. 27-hydroxycholesterol: production rates in normal human subjects. *J Lipid Res* 1999;40:1194–1199.
4. Takahashi S, Fukami T, Masuo Y, et al. Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans. *J Lipid Res* 2016;57:2130–2137.
5. Duez H, Veen JN van der, Duhem C, et al. Regulation of bile acid synthesis by the nuclear receptor Rev-erb α . *Gastroenterology* 2008;135:689–698.

6. Han S, Han SS, Zhang R, et al. Circadian control of bile acid synthesis by a KLF15-Fgf15 axis. *Nat Commun* 2015;6:7231.
7. Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. *Mol Cell* 2000;6:517–526.
8. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. *Cell Metab* 2005;2:217–225.
9. Ridlon JM, Harris SC, Bhowmik S, et al. Consequences of bile salt biotransformations by intestinal bacteria. *Gut Microbes* 2016;7:22–39.
10. Ridlon JM, Kang D-J, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. *J Lipid Res* 2006;47:241–259.
11. Steiner C, Holleboom AG, Karuna R, et al. Lipoprotein distribution and serum concentrations of 7 α -hydroxy-4-cholesten-3-one and bile acids: effects of monogenic disturbances in high-density lipoprotein metabolism. *Clin Sci* 2012;122:385–400.
12. Devlin AS, Fischbach MA. A biosynthetic pathway for a prominent class of microbiota-derived bile acids. *Nat Chem Biol* 2015;11:685–690.
13. Devkota S, Wang Y, Musch MW, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10^{-/-} mice. *Nature* 2012;487:104–108.
14. Joyce SA, MacSharry J, Casey PG, et al. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. *Proc Natl Acad Sci U S A* 2014;111:7421–7426.
15. Swann JR, Want EJ, Geier FM, et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. *Proc Natl Acad Sci U S A* 2011;108 Suppl 1:4523–4530.
16. Sayin SI, Wahlström A, Felin J, et al. Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist. *Cell Metab* 2013;17:225–235.
17. Degirolamo C, Rainaldi S, Bovenga F, et al. Microbiota Modification with Probiotics Induces Hepatic Bile Acid Synthesis via Downregulation of the Fxr-Fgf15 Axis in Mice. *Cell Rep* 2014;7:12–18.
18. Wahlström A, Kovatcheva-Datchary P, Ståhlman M, et al. Induction of FXR signaling in germ-free mice colonized with a human microbiota. *J Lipid Res* 2016;Article in press.
19. Boursier J, Diehl AM. Implication of gut microbiota in nonalcoholic fatty liver disease. *PLoS Pathog* 2015;11:e1004559.
20. Haeusler RA, Astiarraga B, Camastra S, et al. Human insulin resistance is associated with increased plasma levels of 12 α -hydroxylated bile acids. *Diabetes* 2013;62:4184–4191.
21. Lake AD, Novak P, Shipkova P, et al. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. *Toxicol Appl Pharmacol* 2013;268:132–140.
22. Prinz P, Hofmann T, Ahnis A, et al. Plasma bile acids show a positive correlation with body mass index and are negatively associated with cognitive restraint of eating in obese patients. *Front Neurosci* 2015;9:199.
23. Mouzaki M, Wang AY, Bandsma R, et al. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease. *PloS One* 2016;11:e0151829.
24. Vrieze A, Out C, Fuentes S, et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. *J Hepatol* 2014;60:824–831.
25. Jiang C, Xie C, Li F, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. *J Clin Invest* 2015;125:386–402.
26. Stadlbauer V, Leber B, Lemesch S, et al. Lactobacillus casei Shirota Supplementation Does Not Restore Gut Microbiota Composition and Gut Barrier in Metabolic Syndrome: A Randomized Pilot Study. *PloS One* 2015;10:e0141399.

27. Reijnders D, Goossens GH, Hermes GDA, et al. Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial. *Cell Metab* 2016;24:63–74.
28. Lackey DE, Olefsky JM. Regulation of metabolism by the innate immune system. *Nat Rev Endocrinol* 2016;12:15–28.
29. Li T, Jahan A, Chiang JYL. Bile acids and cytokines inhibit the human cholesterol 7 α -hydroxylase gene via the JNK/c-Jun pathway. *Hepatology* 2006;43:1202–1210.
30. Ferslew BC, Xie G, Johnston CK, et al. Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis. *Dig Dis Sci* 2015;60:3318–3328.
31. Aranha MM, Cortez-Pinto H, Costa A, et al. Bile acid levels are increased in the liver of patients with steatohepatitis. *Eur J Gastroenterol Hepatol* 2008;20:519–525.
32. Spinelli V, Lalloyer F, Baud G, et al. Influence of Roux-en-Y gastric bypass on plasma bile acid profiles: a comparative study between rats, pigs and humans. *Int J Obes* 2005 2016;40:1260–1267.
33. Jansen PLM, Werven J van, Aarts E, et al. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. *Dig Dis Basel Switz* 2011;29:48–51.
34. Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. *Endocrinology* 2012;153:3613–3619.
35. Dutia R, Embrey M, O'Brien CS, et al. Temporal changes in bile acid levels and 12 α -hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. *Int J Obes* 2005 2015;39:806–813.
36. Simonen M, Dali-Youcef N, Kaminska D, et al. Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. *Obes Surg* 2012;22:1473–1480.
37. Werling M, Vincent RP, Cross GF, et al. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. *Scand J Gastroenterol* 2013;48:1257–1264.
38. Steinert RE, Peterli R, Keller S, et al. Bile acids and gut peptide secretion after bariatric surgery: A 1-year prospective randomized pilot trial. *Obesity* 2013;21:E660–E668.
39. Kohli R, Bradley D, Setchell KD, et al. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. *J Clin Endocrinol Metab* 2013;98:E708–712.
40. Ahmad NN, Pfalzer A, Kaplan LM. Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. *Int J Obes* 2013;37:1553–1559.
41. Sachdev S, Wang Q, Billington C, et al. FGF 19 and Bile Acids Increase Following Roux-en-Y Gastric Bypass but Not After Medical Management in Patients with Type 2 Diabetes. *Obes Surg* 2016;26:957–965.
42. Dirksen C, Jørgensen NB, Bojsen-Møller KN, et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. *Int J Obes* 2005 2013;37:1452–1459.
43. Gerhard GS, Styer AM, Wood GC, et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. *Diabetes Care* 2013;36:1859–1864.
44. Haluzíková D, Lacinová Z, Kaválková P, et al. Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. *Obes Silver Spring Md* 2013;21:1335–1342.
45. Goncalves D, Barataud A, De Vadder F, et al. Bile Routing Modification Reproduces Key Features of Gastric Bypass in Rat. *Ann Surg* 2015;262:1006–1015.

46. Bhutta HY, Rajpal N, White W, et al. Effect of Roux-en-Y gastric bypass surgery on bile acid metabolism in normal and obese diabetic rats. *PloS One* 2015;10:e0122273.
47. Liou AP, Paziuk M, Luevano J-M, et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. *Sci Transl Med* 2013;5:178ra41.
48. Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. *Nature* 2014;509:183–188.
49. Patti M-E, Houten SM, Bianco AC, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. *Obes Silver Spring Md* 2009;17:1671–1677.
50. Ding L, Sousa KM, Jin L, et al. Vertical sleeve gastrectomy activates GPBAR-1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice. *Hepatology* 2016;64:760–773.
51. McGavigan AK, Garibay D, Henseler ZM, et al. TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice. *Gut* 2015;[Epub ahead of print]:gutjnl-2015-309871.
52. Wang H, Chen J, Hollister K, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. *Mol Cell* 1999;3:543–553.
53. Makishima M, Lu TT, Xie W, et al. Vitamin D receptor as an intestinal bile acid sensor. *Science* 2002;296:1313–1316.
54. Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. *Proc Natl Acad Sci U S A* 2001;98:3369–3374.
55. Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. *J Biol Chem* 2003;278:9435–9440.
56. Nagahashi M, Yuza K, Hirose Y, et al. The roles of bile acids and sphingosine-1-phosphate signaling in the hepatobiliary diseases. *J Lipid Res* 2016;57:1636–1643.
57. Sheikh Abdul Kadir SH, Miragoli M, Abu-Hayyeh S, et al. Bile acid-induced arrhythmia is mediated by muscarinic M2 receptors in neonatal rat cardiomyocytes. *PloS One* 2010;5:e9689.
58. Han S, Chiang JYL. Mechanism of vitamin D receptor inhibition of cholesterol 7 α -hydroxylase gene transcription in human hepatocytes. *Drug Metab Dispos Biol Fate Chem* 2009;37:469–478.
59. Moore LB, Maglich JM, McKee DD, et al. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. *Mol Endocrinol* 2002;16:977–986.
60. Lee JM, Wagner M, Xiao R, et al. Nutrient-sensing nuclear receptors coordinate autophagy. *Nature* 2014;516:112–115.
61. Seok S, Fu T, Choi S-E, et al. Transcriptional regulation of autophagy by an FXR-CREB axis. *Nature* 2014;516:108–111.
62. Berrabah W, Aumercier P, Gheeraert C, et al. Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR). *Hepatology* 2014;59:2022–2033.
63. Kemper JK, Xiao Z, Ponugoti B, et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. *Cell Metab* 2009;10:392–404.
64. Lien F, Berthier A, Bouchaert E, et al. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. *J Clin Invest* 2014;124:1037–1051.
65. Gineste R, Sirvent A, Paumelle R, et al. Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. *Mol Endocrinol* 2008;22:2433–2447.

66. Hashiguchi T, Arakawa S, Takahashi S, et al. Phosphorylation of Farnesoid X Receptor at Serine 154 Links Ligand Activation With Degradation. *Mol Endocrinol* 2016;30:1070–1080.
67. Kim D-H, Xiao Z, Kwon S, et al. A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity. *EMBO J* 2015;34:184–199.
68. Reimann F, Habib AM, Tolhurst G, et al. Glucose sensing in L cells: a primary cell study. *Cell Metab* 2008;8:532–539.
69. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. *Cell Metab* 2009;10:167–177.
70. Nagahashi M, Takabe K, Liu R, et al. Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression. *Hepatology* 2015;61:1216–1226.
71. Cariou B, Harmelen K van, Duran-Sandoval D, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. *J Biol Chem* 2006;281:11039–11049.
72. Abdelkarim M, Caron S, Duhem C, et al. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways. *J Biol Chem* 2010;285:36759–36767.
73. Watanabe M, Houten SM, Matakai C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. *Nature* 2006;439:484–489.
74. Broeders EPM, Nascimento EBM, Havekes B, et al. The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity. *Cell Metab* 2015;22:418–426.
75. Parséus A, Sommer N, Sommer F, et al. Microbiota-induced obesity requires farnesoid X receptor. *Gut* 2016.
76. Rizzo G, Disante M, Mencarelli A, et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. *Mol Pharmacol* 2006;70:1164–1173.
77. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. *Endocrinology* 2004;145:2594–2603.
78. Fang S, Suh JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. *Nat Med* 2015;21:159–165.
79. Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. *J Clin Invest* 2004;113:1408–1418.
80. Bhatnagar S, Damron HA, Hillgartner FB. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. *J Biol Chem* 2009;284:10023–10033.
81. Hirokane H, Nakahara M, Tachibana S, et al. Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. *J Biol Chem* 2004;279:45685–45692.
82. Kast HR, Nguyen CM, Sinal CJ, et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. *Mol Endocrinol* 2001;15:1720–1728.
83. Claudel T, Inoue Y, Barbier O, et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. *Gastroenterology* 2003;125:544–555.
84. Sirvent A, Claudel T, Martin G, et al. The farnesoid X receptor induces very low density lipoprotein receptor gene expression. *FEBS Lett* 2004;566:173–177.
85. Chennamsetty I, Claudel T, Kostner KM, et al. FGF19 signaling cascade suppresses APOA gene expression. *Arterioscler Thromb Vasc Biol* 2012;32:1220–1227.
86. Claudel T, Sturm E, Duez H, et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. *J Clin Invest* 2002;109:961–971.

87. Zhang Y, Yin L, Anderson J, et al. Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. *J Biol Chem* 2010;285:3035–3043.
88. Gautier T, Haan W de, Grober J, et al. Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice. *J Lipid Res* 2013;54:2195–2205.
89. Wang Y, Jones PJH, Woollett LA, et al. Effects of chenodeoxycholic acid and deoxycholic acid on cholesterol absorption and metabolism in humans. *Transl Res J Lab Clin Med* 2006;148:37–45.
90. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. *Lancet Lond Engl* 2015;385:956–965.
91. Nilsson L-M, Abrahamsson A, Sahlin S, et al. Bile acids and lipoprotein metabolism: effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression. *Biochem Biophys Res Commun* 2007;357:707–711.
92. Xu Y, Li F, Zalzal M, et al. Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice. *Hepatology* 2016;64:1072–1085.
93. Ferrell JM, Boehme S, Li F, et al. Cholesterol 7 α -hydroxylase-deficient mice are protected from high-fat/high-cholesterol diet-induced metabolic disorders. *J Lipid Res* 2016;57:1144–1154.
94. Boer JF de, Schonewille M, Boesjes M, et al. Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice. *Gastroenterology* 2017:Article in press.
95. Anon. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. *JAMA* 1984;251:351–364.
96. Zweers SJLB, Booij KAC, Komuta M, et al. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. *Hepatology* 2012;55:575–583.
97. Picard A, Soyer J, Berney X, et al. A Genetic Screen Identifies Hypothalamic Fgf15 as a Regulator of Glucagon Secretion. *Cell Rep* 2016;17:1795–1806.
98. Dijk TH van, Grefhorst A, Oosterveer MH, et al. An increased flux through the glucose 6-phosphate pool in enterocytes delays glucose absorption in Fxr^{-/-} mice. *J Biol Chem* 2009;284:10315–10323.
99. Duran-Sandoval D, Cariou B, Percevault F, et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. *J Biol Chem* 2005;280:29971–29979.
100. Caron S, Huaman Samanez C, Dehondt H, et al. Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes. *Mol Cell Biol* 2013;33:2202–2211.
101. Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. *Science* 2011;331:1621–1624.
102. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. *Biochem Biophys Res Commun* 2005;329:386–390.
103. Brighton CA, Rievaj J, Kuhre RE, et al. Bile Acids Trigger GLP-1 Release Predominantly by Accessing Basolaterally Located G Protein-Coupled Bile Acid Receptors. *Endocrinology* 2015;156:3961–3970.
104. Trabelsi M-S, Daoudi M, Prawitt J, et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. *Nat Commun* 2015;6:7629.

105. Popescu IR, Helleboid-Chapman A, Lucas A, et al. The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity. *FEBS Lett* 2010;584:2845–2851.
106. Kumar DP, Rajagopal S, Mahavadi S, et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells. *Biochem Biophys Res Commun* 2012;427:600–605.
107. Kumar DP, Asgharpour A, Mirshahi F, et al. Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet α Cells to Promote Glucose Homeostasis. *J Biol Chem* 2016;291:6626–6640.
108. Seyer P, Vallois D, Poitry-Yamate C, et al. Hepatic glucose sensing is required to preserve β cell glucose competence. *J Clin Invest* 2013;123:1662–1676.
109. Smushkin G, Sathananthan M, Piccinini F, et al. The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. *Diabetes* 2013;62:1094–1101.
110. Li F, Jiang C, Krausz KW, et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. *Nat Commun* 2013;4:2384.
111. Jiang C, Xie C, Lv Y, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. *Nat Commun* 2015;6:10166.
112. McGettigan BM, McMahan RH, Luo Y, et al. Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease. *J Biol Chem* 2016;291:23058–23067.
113. Kaur A, Patankar JV, Haan W de, et al. Loss of Cyp8b1 improves glucose homeostasis by increasing GLP-1. *Diabetes* 2015;64:1168–1179.
114. Yamagata K, Daitoku H, Shimamoto Y, et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. *J Biol Chem* 2004;279:23158–23165.
115. Ma K, Saha PK, Chan L, et al. Farnesoid X receptor is essential for normal glucose homeostasis. *J Clin Invest* 2006;116:1102–1109.
116. Stayrook KR, Bramlett KS, Savkur RS, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. *Endocrinology* 2005;146:984–991.
117. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. *Gastroenterology* 2013;145:574–582.e1.
118. Lewis ND, Patnaude LA, Pelletier J, et al. A GPBAR1 (TGR5) small molecule agonist shows specific inhibitory effects on myeloid cell activation in vitro and reduces experimental autoimmune encephalitis (EAE) in vivo. *PloS One* 2014;9:e100883.
119. Keitel V, Donner M, Winandy S, et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells. *Biochem Biophys Res Commun* 2008;372:78–84.
120. Ichikawa R, Takayama T, Yoneno K, et al. Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway. *Immunology* 2012;136:153–162.
121. Guo C, Xie S, Chi Z, et al. Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome. *Immunity* 2016;45:802–816.
122. Wang Y-D, Chen W-D, Yu D, et al. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF- κ B) in mice. *Hepatology* 2011;54:1421–1432.
123. Pols TWH, Nomura M, Harach T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. *Cell Metab* 2011;14:747–757.

124. Liu H, Pathak P, Boehme S, et al. Cholesterol 7 α -hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis. *J Lipid Res* 2016;57:1831–1844.
125. Gadaleta RM, Erpecum KJ van, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. *Gut* 2011;60:463–472.
126. Vavassori P, Mencarelli A, Renga B, et al. The bile acid receptor FXR is a modulator of intestinal innate immunity. *J Immunol* 2009;183:6251–6261.
127. Inagaki T, Moschetta A, Lee Y-K, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. *Proc Natl Acad Sci U S A* 2006;103:3920–3925.
128. Schiöth HB, Boström A, Murphy SK, et al. A targeted analysis reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug metabolism in non-alcoholic fatty liver disease. *BMC Genomics* 2016;17:462.
129. Verbeke L, Mannaerts I, Schierwagen R, et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. *Sci Rep* 2016;6:33453.
130. Fickert P, Fuchsbichler A, Moustafa T, et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. *Am J Pathol* 2009;175:2392–2405.
131. Feaver RE, Cole BK, Lawson MJ, et al. Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis. *JCI Insight* 2016;1:e90954.
132. Pencek R, Marmon T, Roth JD, et al. Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers. *Diabetes Obes Metab* 2016;18:936–940.
133. Camilleri M, Gores GJ. Therapeutic targeting of bile acids. *Am J Physiol Gastrointest Liver Physiol* 2015;309:G209–215.
134. Schaap FG, Trauner M, Jansen PLM. Bile acid receptors as targets for drug development. *Nat Rev Gastroenterol Hepatol* 2014;11:55–67.
135. Duan H, Ning M, Zou Q, et al. Discovery of Intestinal Targeted TGR5 Agonists for the Treatment of Type 2 Diabetes. *J Med Chem* 2015;58:3315–3328.
136. Briere DA, Ruan X, Cheng CC, et al. Novel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in Mice. *PloS One* 2015;10:e0136873.
137. Alemi F, Kwon E, Poole DP, et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. *J Clin Invest* 2013;123:1513–1530.
138. Ge H, Zhang J, Gong Y, et al. Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions. *J Biol Chem* 2014;289:30470–30480.
139. Rao A, Kusters A, Mells JE, et al. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. *Sci Transl Med* 2016;8:357ra122.
140. Beraza N, Ofner-Ziegenfuss L, Ehedego H, et al. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. *Gut* 2011;60:387–396.
141. Trauner M, Halilbasic E, Claudel T, et al. Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders. *Dig Dis Basel Switz* 2015;33:433–439.
142. Mueller M, Thorell A, Claudel T, et al. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. *J Hepatol* 2015;62:1398–1404.
143. Downes M, Verdecia MA, Roecker AJ, et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. *Mol Cell* 2003;11:1079–1092.

Figure legends

Figure 1: Role of BA in the control of metabolic and immune homeostasis *via* activation of their receptors FXR and TGR5.

See text and Supplemental references 2 for details.

Abbreviations: BA (bile acids); TGR5 (Takeda G protein-coupled receptor 5); FXR (farnesoid X receptor); FGF15/19 (fibroblast growth factor 15/19); Lp (lipoprotein); HDL (high density lipoprotein); IDL (intermediary density lipoprotein); LDL (low density lipoprotein); Lp(a) (lipoprotein (a)); VLDL (very low density lipoprotein); GLP-1 (glucagon-like peptide-1); ASBT (apical-sodium-dependent BA transporter); TNF α (tumor necrosis factor alpha); IL (interleukin); COX (cyclooxygenase).

Figure 2: BA control lipoprotein metabolism through hepatic and intestinal FXR activation.

FXR and FGF15/19 decrease hepatic lipogenesis. VLDL secretion, apoB and MTP synthesis are inhibited by FXR. Increased ApoCII and diminished ApoCIII enhance LPL-mediated intravascular lipolysis, and thus promote conversion of VLDL to IDL and LDL. FXR inhibits BA synthesis from cholesterol. As a consequence, hepatic cholesterol concentrations increase and LDL-R activity decreases. SR-B1 induction enhances selective CE uptake, and associated with increased CETP and decreased ApoA1 lowers HDL-C. In rodents, FXR enhances TICE by changing the hydrophobicity index. This effect is thus likely to occur in the opposite direction in humans (shown in figure). Inhibition of hepatic synthesis of apo(a) by hepatic FXR and intestinal FGF19 decreases Lp(a).

Abbreviations: Apo (apolipoprotein); BA (bile acids); C (cholesterol); CETP (cholesteryl ester transfer protein); CDCA (chenodesoxycholic acid); CE (cholesteryl esters); FGF15/19 (fibroblast growth factor 15/19); HDL (high density lipoprotein); IDL (intermediary density lipoprotein); LDL (low density lipoprotein); Lp(a) (lipoprotein (a)); MTP (microsomal transfer protein); SR-B1 (scavenger receptor type 1); TICE (trans-intestinal cholesterol excretion); VLDL (very low density lipoprotein).

Figure 3: Modulation of glucose homeostasis by BA.

FXR activation in the enterocyte modulates the absorption of glucose (1) and BA (2), and induces FGF15/19 secretion (3). In the liver, FXR activation decreases glycolysis and lipogenesis *via* inhibition of ChREBP (4) and SREBP1c (5), respectively, hence decreasing VLDL-TG production. Insulin *via* the INSR (6) modulates the proportion of 12 α -OH BA by repressing FoxO1, a CYP8B1 activator. Intestinal FGF15/19 activates hepatic FGFR4/ β Klotho (7), which decreases GS phosphorylation by inhibiting GSK3 β , increasing glycogenesis and decreasing glycemia. In entero-endocrine L-cells, BA increase *-via* TGR5- (8) or decrease *-via* FXR through ChREBP- (9) proglucagon gene expression and GLP-1 secretion. TGR5 activation in pancreatic α -cells induces pro-convertase-1, shifting proglucagon processing from glucagon to GLP-1 (10). FXR and TGR5 activation in pancreatic β -cells promotes insulin secretion, lowering glycemia (11). BA synthesis in the hepatocyte is decreased by FGF15/19-FGFR4/ β Klotho activation and FXR activation *via* SHP-LRH-1 (12).

Abbreviations: AcCoA (acetyl co-enzyme A); Apo (apolipoprotein); ASBT (apical-sodium-dependent BA transporter); BA (bile acids); BSEP (bile salt export protein); C (cholesterol); CYP7A1 (cytochrome P450 7 α -hydroxylase A1) ; CYP8B1 (cytochrome P450 12 α -hydroxylase B1); FGF15/19 (fibroblast growth factor 15/19); FXR

(farnesoid X receptor); GLP-1 (glucagon-like peptide-1); GS (glycogen synthase); GSK3 (glycogen synthase kinase 3); INSR (insulin receptor); SHP (short heterodimer protein); TGR5 (Takeda G protein-coupled receptor 5); L-PK (liver pyruvate kinase); OST α/β (organic solute transporters α and β); VLDL (very low density lipoprotein).

Figure 4: Differential effects of FXR inhibition vs activation in liver and intestine on metabolism, inflammation and fibrosis.

See text and supplemental references 3 for details.

Abbreviations: AMPK (AMP-activated protein kinase); ChREBP (carbohydrate responsive element binding protein); ER (endoplasmic reticulum); FGF15/19 (fibroblast growth factor 15/19); GLP-1 (glucagon-like peptide-1); HSC (hepatic stellate cell); LKB1 (liver kinase B1); L-PK (liver pyruvate kinase); miR (micro RNA); SHP (small heterodimer protein); SREBP1c (sterol responsive element binding protein 1); WAT (white adipose tissue).

Table: Influence of obesity, insulin resistance, type 2 diabetes, NAFLD and bariatric surgery (Roux-en-Y gastric bypass, vertical sleeve gastrectomy, bilio-pancreatic diversion and adjustable gastric banding) on peripheral blood bile acid concentrations.

OBESITY / IR / T2D / NAFLD					
Case (n)	Controls (n)	Feeding state	Methodology	Outcome	Reference
85 obese	15	fasting	Enzymatic assay	Total BA concentrations positively correlated with BMI	Prinz 2015 ¹
15 T2D	15 non-diabetic, BMI-matched controls	fasting OGTT low-fat, medium-fat, high-fat meal test	UPLC-MS/MS	Fasting: ↑ total BA concentrations compared with non-diabetic controls Post-prandial: ↑ total BA concentrations in all the feeding states, positively correlated with increasing meal fat content compared with non-diabetic controls	Sonne 2016 ²
35 T2D	200 non-diabetic patients classified into quartiles based on IR	fasting	LC-MS	T2D patients: ↑total BA concentrations without changes in the 12α-hydroxy:non-12α-hydroxy-BA ratio Non-diabetic IR patients: ↑ 12α-hydroxy:non-12α-hydroxy-BA ratio associated with ↓ insulin sensitivity and ↑ plasma TGs	Haeusler 2013 ³
12 T2D	12 matched non-diabetic controls	fasting meal test	HPLC-MS/MS	Fasting: no changes in total BA in T2D compared with non-diabetic controls Post-prandial: ↑total and Glyco-BA in T2D compared with non-diabetic controls	Vincent 2013 ⁴
12 T2D	62 non-diabetic volunteers	fasting	HPLC-MS/MS	Fasting: ↑ tauro BA in T2D patients compared with non-diabetic controls	Wewalka 20014 ⁵
20 T2D 22 obese	14 healthy	fasting	GC-MS	↑ total BA concentrations in obese and T2D patients compared with controls ↑DCA in T2D compared with controls ↑CA in obese patients compared with controls CDCA and CA, and to a lesser extent DCA, positively associated to IR in obese and T2D patients	Cariou 2011 ⁶

7 NASH	15 healthy	fasting post-prandial	LC-MS/MS	Fasting and post-prandial: ↑ total BA concentrations in NASH compared with controls due to conjugated species	Ferslew 2015 ⁷
--------	------------	--------------------------	----------	---	---------------------------

ROUX-EN-Y GASTRIC BYPASS

Case (n)	Controls (n)	Feeding state	Time after surgery	Methodology	Outcome	Reference
9	/	fasting	2y, 4y	HPLC-MS/MS	2y, 4y: ↑ total BA	Patti 2009 ⁸
19	/	fasting	1m, 3m	HPLC-MS	1m, 3m: ↑ total BA	Nakatani 2009 ⁹
35	/	fasting	3m	Enzymatic assay	3m: ↑ total BA	Jansen 2011 ¹⁰
12	/	fasting	4d, 42d	LC-MS/MS	42d: ↑ total BA	Pournaras 2012 ¹¹
30	/	fasting	1y	Enzymatic assay, HPLC-MS/MS	1y: ↑ total BA; ↓ tauro-BA	Simonen 2012 ¹²
36 T2D-R 21 T2D-NR	37	fasting	1y	LC-MS/MS	1y: ↑ total BA in T2D-R	Gerhard 2013 ¹³
8	/	fasting	After 20% of weight loss	LC-MS	↑ total BA	Kohli 2013 ¹⁴
21	/	fasting	1m, 6m, 1y, 2y	LC-MS/MS	1m: ↑ total BA due to UDCA, TUDCA, GUDCA 2y: ↑ total BA due to CA, CDCA, DCA, GDCA, HCA 6m, 1y: no changes in total BA	Albaugh 2015 ¹⁵
15	/	fasting	1y	LC-MS	No changes in total BA	Sachdev 2016 ¹⁶
7	6	fasting	1w, 3m, 1y	GC-MS	1w, 3m: no changes in total BA 1y: ↑ total BA	Steinert 2013 ¹⁷

63	/	fasting	15m	HPLC-MS/MS	15m: ↑ total BA	Werling 2013 ¹⁸
13	/	fasting	1m, 2y	HPLC-MS/MS	1m: ↓ total BA 2y: ↑ total BA and ↑ 12α-hydroxylated/non12α-hydroxylated BA ratio	Dutia 2015 ¹⁹
13 T2D 12 non-diabetic	/	fasting	1w, 3m, 1y	HPLC-MS/MS	1w: ↓ total BA in non-diabetic patients 3m, 1y: ↑ total BA in T2D and non-diabetic patients	Jørgensen 2015 ²⁰
15	/	meal test	1y	LC-MS	1y: ↑ total BA due to conjugated BA	Sachdev 2016 ¹⁶
7	6	meal test	1w, 3m, 1y	GC-MS	1w, 3m: no changes in total BA 1y: ↑ total BA	Steinert 2013 ¹⁷
5	8	meal test	1w, 4w, 40w	HPLC-MS	4w, 40w: ↑total BA	Ahmad 2013 ²¹
13 T2D 12 non-diabetic	/	meal test	1w, 3m, 1y	HPLC-MS/MS	1w: ↑ total BA in non-diabetic patients 3m, 1y: ↑ total BA in T2D and non-diabetic patients	Jørgensen 2015 ²⁰
63	/	OGTT	15m	HPLC-MS/MS	15m: ↑ total BAs due to glyco-conjugated BA	Werling 2013 ¹⁸
13	/	OGTT	1m, 2y	HPLC-MS/MS	1m: unchanged total BA 2y: ↑ total BA and ↑ 12α-hydroxylated:non12α-hydroxylated BA ratio	Dutia 2015 ¹⁹
8	/	post-prandial	After 20% of weight loss	LC-MS	↑ total BA	Kohli 2013 ¹⁴
16 GBMIL 14 PBMIL	8	post-prandial	1y	Enzymatic assay	1y: ↑ total BA in GBMIL and PBMIL compared with lean controls No changes between GBMIL and PBMIL	Dirksen 2013 ²²

VERTICAL SLEEVE GASTRECTOMY						
Case (n)	Lean controls (n)	Feeding state	Time after surgery	Methodology	Outcome	Reference
7	6	fasting meal test	1w, 3m, 1y	GC-MS	Fasting 1w, 3m: no changes; 1y: ↑total BA Post-prandial: no changes in total BA	Steinert 2013 ¹⁷
17	/	fasting	6m, 1y, 2y	GC-MS	6m, 1y, 2y: no changes in total BA	Haluzíková 2013 ²³
BILIO-PANCREATIC DIVERSION						
Case (n)	Controls (n)	Feeding state	Time after surgery	Methodology	Outcome	Reference
15	10 BMI-matched non-surgical	fasting	7w, 53w	LC-MS/MS	7w: ↑ total BA mainly due to free BA 53w: ↑ total BA, but lower than 7w	Ferrannini 2015 ²⁴
LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING						
Case (n)	Controls (n)	Feeding state	Time after surgery	Methodology	Outcome	Reference
6	/	fasting	4d, 42d	LC-MS/MS	No changes in total BA	Pournaras 2012 ¹¹
10	/	fasting + post-prandial	After 20% of weight loss	LC-MS	Fasting: ↓ total BA Post-prandial: no changes in total BA	Kohli 2013 ¹⁴

References included in Supplemental references 1

Abbreviations: BMI (body mass index); d (days); GBMIL (patients with good body mass index loss after RYGB); GC-MS (gas chromatography–mass spectrometry); IR (insulin resistance); LC-MS (liquid chromatography–mass spectrometry); LC-MS/MS (chromatography–tandem mass spectrometry); m (months); OGTT (oral glucose tolerance test); PBMIL (patients with poor body mass index loss after RYGB); RYGB (Roux-en-y gastric bypass); TG (triglycerides); T2D (type 2 diabetes); T2D-NR (type 2 diabetes without remission); T2D-R (type 2 diabetes with remission); UPLC-MS/MS (ultra-performance liquid chromatography-tandem mass spectrometer); w (weeks); y (years).

Figure 1

Figure 2

Figure 3

Figure 4

Supplemental references 1

1. Prinz P, Hofmann T, Ahnis A, et al. Plasma bile acids show a positive correlation with body mass index and are negatively associated with cognitive restraint of eating in obese patients. *Front Neurosci* 2015;9:199.
2. Sonne DP, Nierop FS van, Kulik W, et al. Postprandial Plasma Concentrations of Individual Bile Acids and FGF-19 in Patients With Type 2 Diabetes. *J Clin Endocrinol Metab* 2016;101:3002–3009.
3. Haeusler RA, Astiarraga B, Camastra S, et al. Human insulin resistance is associated with increased plasma levels of 12 α -hydroxylated bile acids. *Diabetes* 2013;62:4184–4191.
4. Vincent RP, Omar S, Ghozlan S, et al. Higher circulating bile acid concentrations in obese patients with type 2 diabetes. *Ann Clin Biochem* 2013;50:360–364.
5. Wewalka M, Patti M-E, Barbato C, et al. Fasting serum taurine-conjugated bile acids are elevated in type 2 diabetes and do not change with intensification of insulin. *J Clin Endocrinol Metab* 2014;99:1442–1451.
6. Cariou B, Chetiveaux M, Zaïr Y, et al. Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults. *Nutr Metab* 2011;8:48.
7. Ferslew BC, Xie G, Johnston CK, et al. Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis. *Dig Dis Sci* 2015;60:3318–3328.
8. Patti M-E, Houten SM, Bianco AC, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. *Obes Silver Spring Md* 2009;17:1671–1677.
9. Nakatani H, Kasama K, Oshiro T, et al. Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. *Metabolism* 2009;58:1400–1407.
10. Jansen PLM, Werven J van, Aarts E, et al. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. *Dig Dis* 2011;29:48–51.
11. Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. *Endocrinology* 2012;153:3613–3619.
12. Simonen M, Dali-Youcef N, Kaminska D, et al. Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. *Obes Surg* 2012;22:1473–1480.
13. Gerhard GS, Styer AM, Wood GC, et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. *Diabetes Care* 2013;36:1859–1864.

14. Kohli R, Bradley D, Setchell KD, et al. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. *J Clin Endocrinol Metab* 2013;98:E708-712.
15. Albaugh VL, Flynn CR, Cai S, et al. Early Increases in Bile Acids Post Roux-en-Y Gastric Bypass Are Driven by Insulin-Sensitizing, Secondary Bile Acids. *J Clin Endocrinol Metab* 2015;100:E1225-1233.
16. Sachdev S, Wang Q, Billington C, et al. FGF 19 and Bile Acids Increase Following Roux-en-Y Gastric Bypass but Not After Medical Management in Patients with Type 2 Diabetes. *Obes Surg* 2016;26:957–965.
17. Steinert RE, Peterli R, Keller S, et al. Bile acids and gut peptide secretion after bariatric surgery: A 1-year prospective randomized pilot trial. *Obesity* 2013;21:E660–E668.
18. Werling M, Vincent RP, Cross GF, et al. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. *Scand J Gastroenterol* 2013;48:1257–1264.
19. Dutia R, Embrey M, O'Brien CS, et al. Temporal changes in bile acid levels and 12 α -hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. *Int J Obes* 2015;39:806–813.
20. Jørgensen NB, Dirksen C, Bojsen-Møller KN, et al. Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations. *J Clin Endocrinol Metab* 2015;100:E396-406.
21. Ahmad NN, Pfalzer A, Kaplan LM. Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. *Int J Obes* 2013;37:1553–1559.
22. Dirksen C, Jørgensen NB, Bojsen-Møller KN, et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. *Int J Obes* 2013;37:1452–1459.
23. Haluzíková D, Lacinová Z, Kaválková P, et al. Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. *Obes Silver Spring Md* 2013;21:1335–1342.
24. Ferrannini E, Camastra S, Astiarraga B, et al. Increased Bile Acid Synthesis and Deconjugation After Biliopancreatic Diversion. *Diabetes* 2015;64:3377–3385.

Supplemental references 2

1. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. *Physiol Rev* 2009;89:147–191.
2. Pircher PC, Kitto JL, Petrowski ML, et al. Farnesoid X receptor regulates bile acid-amino acid conjugation. *J Biol Chem* 2003;278:27703–27711.
3. Ananthanarayanan M, Balasubramanian N, Makishima M, et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. *J Biol Chem* 2001;276:28857–28865.
4. Boyer JL, Trauner M, Mennone A, et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. *Am J Physiol Gastrointest Liver Physiol* 2006;290:G1124-1130.
5. Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. *Science* 2011;331:1621–1624.
6. Caron S, Huaman Samanez C, Dehondt H, et al. Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes. *Mol Cell Biol* 2013;33:2202–2211.
7. Zhang L, Wang Y-D, Chen W-D, et al. Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice. *Hepatol Baltim Md* 2012;56:2336–2343.
8. Verbeke L, Mannaerts I, Schierwagen R, et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. *Sci Rep* 2016;6:33453.
9. Fickert P, Fuchsbichler A, Moustafa T, et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. *Am J Pathol* 2009;175:2392–2405.
10. Kumar DP, Asgharpour A, Mirshahi F, et al. Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet α Cells to Promote Glucose Homeostasis. *J Biol Chem* 2016;291:6626–6640.
11. Popescu IR, Helleboid-Chapman A, Lucas A, et al. The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity. *FEBS Lett* 2010;584:2845–2851.
12. Renga B, Mencarelli A, Vavassori P, et al. The bile acid sensor FXR regulates insulin transcription and secretion. *Biochim Biophys Acta* 2010;1802:363–372.
13. Kumar DP, Rajagopal S, Mahavadi S, et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells. *Biochem Biophys Res Commun* 2012;427:600–605.
14. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. *Cell Metab* 2005;2:217–225.
15. Neimark E, Chen F, Li X, et al. Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. *Hepatol* 2004;40:149–156.

16. Dijk TH van, Grefhorst A, Oosterveer MH, et al. An increased flux through the glucose 6-phosphate pool in enterocytes delays glucose absorption in Fxr^{-/-} mice. *J Biol Chem* 2009;284:10315–10323.
17. Gadaleta RM, Erpecum KJ van, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. *Gut* 2011;60:463–472.
18. Inagaki T, Moschetta A, Lee Y-K, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. *Proc Natl Acad Sci U S A* 2006;103:3920–3925.
19. Trabelsi M-S, Daoudi M, Prawitt J, et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. *Nat Commun* 2015;6:7629.
20. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. *Biochem Biophys Res Commun* 2005;329:386–390.
21. Watanabe M, Houten SM, Matakai C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. *Nature* 2006;439:484–489.
22. Abdelkarim M, Caron S, Duhem C, et al. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor- γ and interfering with the Wnt/ β -catenin pathways. *J Biol Chem* 2010;285:36759–36767.
23. Pols TWH, Nomura M, Harach T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. *Cell Metab* 2011;14:747–757.
24. Guo C, Xie S, Chi Z, et al. Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome. *Immunity* 2016;45:802–816.
25. Keitel V, Donner M, Winandy S, et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells. *Biochem Biophys Res Commun* 2008;372:78–84.
26. Ichikawa R, Takayama T, Yoneno K, et al. Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway. *Immunology* 2012;136:153–162.

Supplemental references 3

1. Zhou M, Learned RM, Rossi SJ, et al. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. *Hepatology* 2016;63:914–929.
2. Fang S, Suh JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. *Nat Med* 2015;21:159–165.
3. Gadaleta RM, Erpecum KJ van, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. *Gut* 2011;60:463–472.
4. Inagaki T, Moschetta A, Lee Y-K, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. *Proc Natl Acad Sci U S A* 2006;103:3920–3925.
5. Dijk TH van, Grefhorst A, Oosterveer MH, et al. An increased flux through the glucose 6-phosphate pool in enterocytes delays glucose absorption in *Fxr*^{-/-} mice. *J Biol Chem* 2009;284:10315–10323.
6. Trabelsi M-S, Daoudi M, Prawitt J, et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. *Nat Commun* 2015;6:7629.
7. Jiang C, Xie C, Li F, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. *J Clin Invest* 2015;125:386–402.

8. Jiang C, Xie C, Lv Y, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. *Nat Commun* 2015;6:10166.
9. Li F, Jiang C, Krausz KW, et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. *Nat Commun* 2013;4:2384.
10. Zhang L, Xie C, Nichols RG, et al. Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism. *mSystems* 2016;1.
11. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. *Physiol Rev* 2009;89:147–191.
12. Lian F, Wang Y, Xiao Y, et al. Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis. *Mol Med Rep* 2015;12:5821–5827.
13. Meng Z, Wang Y, Wang L, et al. FXR regulates liver repair after CCl₄-induced toxic injury. *Mol Endocrinol* 2010;24:886–897.
14. Lee CG, Kim YW, Kim EH, et al. Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1. *Gastroenterology* 2012;142:1206–1217.e7.
15. Verbeke L, Mannaerts I, Schierwagen R, et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. *Sci Rep* 2016;6:33453.

16. Fickert P, Fuchsbichler A, Moustafa T, et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. *Am J Pathol* 2009;175:2392–2405.
17. Caron S, Huaman Samanez C, Dehondt H, et al. Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes. *Mol Cell Biol* 2013;33:2202–2211.
18. Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. *J Clin Invest* 2004;113:1408–1418.
19. Xiong X, Wang X, Lu Y, et al. Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice. *J Hepatol* 2014;60:847–854.